This project expands on an ongoing clinical trial comparing psilocybin therapy alone with psilocybin therapy combined with mindfulness training to include patients with more severe depression and new, at-home and in-clinic measurements. In addition, this project also aims to develop, validate, and deploy a multimodal system capable of detecting early affective and cognitive markers of depression and suicidality risk using integrated biosignals. Data collected under this award will be deidentified and housed in the ARPA-H EVIDENT Data Repository.